TY - JOUR
T1 - Five years' clinical use of GnRH antagonists: Evaluation of safety and allergic potential
AU - Engel, J. B.
AU - Schultze-Mosgau, A.
AU - Diedrich, Klaus
PY - 2005/6
Y1 - 2005/6
N2 - Three antagonists of gonadotrophin-releasing hormone are currently clinically available. Cetrorelix (Cetrotide®) and ganirelix (Orgalutran®/Antagon®) have been safely used in assisted reproduction since 1999 and 2000 respectively. The structurally similar abarelix (Plenaxis®) has been approved for the therapy of advanced androgen sensitive prostate cancer. However, due to the occurrence of allergic reactions, its use is restricted to only a subgroup of patients. These allergic side effects may not be due to abarelix, as the drug itself does not have a strong histamine liberating potential in vitro, but could be attributed to carboxymethylcellulose (CMC), which only Plenaxis, but not Cetrotide or Orgalutran/Antagon contain. CMC is used to obtain the sustained-release characteristics of Plenaxis. Since 1973, numerous case reports and studies have been published regarding allergic reactions and specific immunoglobulin E antibodies against CMC. Thus, the allergic side effects of Plenaxis could be rather due to CMC than to abarelix.
AB - Three antagonists of gonadotrophin-releasing hormone are currently clinically available. Cetrorelix (Cetrotide®) and ganirelix (Orgalutran®/Antagon®) have been safely used in assisted reproduction since 1999 and 2000 respectively. The structurally similar abarelix (Plenaxis®) has been approved for the therapy of advanced androgen sensitive prostate cancer. However, due to the occurrence of allergic reactions, its use is restricted to only a subgroup of patients. These allergic side effects may not be due to abarelix, as the drug itself does not have a strong histamine liberating potential in vitro, but could be attributed to carboxymethylcellulose (CMC), which only Plenaxis, but not Cetrotide or Orgalutran/Antagon contain. CMC is used to obtain the sustained-release characteristics of Plenaxis. Since 1973, numerous case reports and studies have been published regarding allergic reactions and specific immunoglobulin E antibodies against CMC. Thus, the allergic side effects of Plenaxis could be rather due to CMC than to abarelix.
UR - http://www.scopus.com/inward/record.url?scp=22244442450&partnerID=8YFLogxK
U2 - 10.1016/S1472-6483(11)60392-1
DO - 10.1016/S1472-6483(11)60392-1
M3 - Journal articles
C2 - 23577417
AN - SCOPUS:22244442450
SN - 1472-6483
VL - 10
SP - 61
EP - 65
JO - Reproductive BioMedicine Online
JF - Reproductive BioMedicine Online
IS - SUPPL. 3
ER -
